Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001070892 | SCV001236171 | pathogenic | not provided | 2024-12-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn264Leufs*9) in the ELOVL4 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 51 amino acid(s) of the ELOVL4 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with autosomal dominant Stargardt disease (PMID: 11138005). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4939). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects ELOVL4 function (PMID: 23509295, 24833735). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001074586 | SCV001240177 | pathogenic | Retinal dystrophy | 2019-01-08 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000005226 | SCV000025404 | pathogenic | Stargardt disease 3 | 2004-04-01 | no assertion criteria provided | literature only |